Onco-Innovations' Inka Health Partners with AstraZeneca Canada

Onco-Innovations Limited announced that its subsidiary, Inka Health Corp., has signed a new analytical contract with AstraZeneca Canada. This agreement, finalized on March 20, 2025, aims to support real-world evidence (RWE) research within Canada's regulatory environment.

The project will focus on creating a peer-reviewed manuscript examining the role of international RWE in submissions to Canada's Drug Agency. This study highlights the strategic use of data generated outside Canada, a significant interest within oncology and pharmaceuticals.

This collaboration builds on prior work under the AZ Services Agreement. Inka Health previously conducted a comprehensive review addressing bias in RWE. Findings were accepted for presentation at ISPOR 2025.